Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds
First Claim
Patent Images
1. A method for treating osteoporosis in a patient in need of such treatment, comprising administering to said patient at least one androgenic steroid having a Ki value for the androgen receptor of less than about 2×
- 10-8 M and an androgen receptor-mediated inhibitory effect on the growth of human breast cancer ZR-75-1 cells which reaches half-maximal value at a concentration below 3.0 nanomoles per liter and no visible masculinizing activity wherein said androgenic steroid is administered at a dosage sufficiently low to maintain a cumulative androgenic steroid serum concentration between 1 and 50 nanomoles per liter for a period of at least 30 days.
0 Assignments
0 Petitions
Accused Products
Abstract
A method of treatment or prevention of breast and endometrial cancer, osteoporosis and endometriosis in susceptible warm-blooded animals comprising administering a low dose of a progestin or other steroid derivative having androgenic activity and low masculinizing activity. Pharmaceutical compositions useful for such treatment and pharmaceutical kits containing such compositions are disclosed. An in vitro assay permitting specific measurements of androgenic activity of potentially useful compounds is also disclosed.
60 Citations
26 Claims
-
1. A method for treating osteoporosis in a patient in need of such treatment, comprising administering to said patient at least one androgenic steroid having a Ki value for the androgen receptor of less than about 2×
- 10-8 M and an androgen receptor-mediated inhibitory effect on the growth of human breast cancer ZR-75-1 cells which reaches half-maximal value at a concentration below 3.0 nanomoles per liter and no visible masculinizing activity wherein said androgenic steroid is administered at a dosage sufficiently low to maintain a cumulative androgenic steroid serum concentration between 1 and 50 nanomoles per liter for a period of at least 30 days.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
- 23. A method for treating osteoporosis in a patient in need of such treatment comprising administering to said patient medroxyprogesterone acetate at a dosage sufficiently low to maintain serum concentration of said medroxyprogesterone acetate between 1 and 50 nanomoles per liter for at least 30 days.
- 25. A method for treating osteoporosis in a patient in need of such treatment comprising administering megestrol acetate to said patient at a dosage sufficiently low to maintain serum concentration of said megestrol acetate between 1 and 50 nanomoles per liter for at least 30 days.
Specification